Table II.

Antiviral Target, 50% Inhibitory Concentration (IC₅₀) Against Rhinoviruses and Assays Used for the Determination of Antiviral Activity of Examples of Highly Active Synthetic Compounds Described in This Review (Chemical Structures are Presented in Figs. 2–4)

		Antiviral activity in vitro
Antiviral target	Synthetic compound	(µM)	Assay	HRV tested	Citation
Capsid binder	Disoxaril	0.01–18.1	Plaque reduction assay	35 serotypes	139
	Pleconaril	0.03–17.5; seven completely resistant HRV‐B	Cell protection assay with crystal violet	All serotypes	12
	Pirodavir	0.003–39.0; four completely resistant HRV	Cell protection assay with MTT	All serotypes	187
	Oxime ether 14	0.002–0.02	Cell protection assay	16 serotypes	141
	Compound 19	0.01	Cell protection assay with crystal violet	HRV‐2	188
	SCH 38057	20.4–29.2	Plaque reduction assay	6 serotypes	191
	Ro 09‐0881	0.01–9.1	Plaque reduction assay	12 serotypes	193
	BW863C	0.007	Plaque reduction assay	HRV‐1B	194
	Isoflavan	∼0.48	Plaque reduction assay	HRV‐1B	137
	MDL 20,957	0.02	Plaque reduction assay	32 serotypes	196
	MDL‐860	3.25a	Virus yield reduction assay	90 serotypes	198
2A and 3C Proteinase	Homophthalimides	4.2	Virus yield reduction assay	HRV‐2 and HRV‐14	215
3C Proteinase	Rupintrivir	0.003–0.08	Cell protection assay with XTT	48 serotypes	227
	Compound 1	0.014–0.12	Cell protection assay with XTT	35 serotypes	231
RNA synthesis	2‐Furylmercury chloride	0.02–2.5; 4 completely resistant HRV	Not described	17 serotypes	235
	Ribavirin	73.8 and 123.0 102.5 and 159.8	Cell protection assay Plaque reduction assay	HRV‐2 and HRV‐14, resp.	239
	Enviroxime	0.17–1.0	Plaque reduction assay	15 serotypes	244
		0.03–0.2	Cell protection assay with crystal violet	12 serotypes	245

^{a a}1 µg/mL reduced the virus yield of 72 serotypes by at least 1.0 log₁₀, 12 serotypes were intermediately inhibited, and 6 not.